Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

SARS-CoV-2 ANTIVIRALS AND OUTCOMES

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 11 of 11
SYMPTOM DURATION IN COVID-19 CONVALESCENT PATIENTS: REGIONAL & CLINICAL ASSOCIATIONS   (ABSTRACT 97)
Jorge A Gallardo-Cartagena
Universidad Nacional Mayor de San Marcos, Bellavista, CALLAO, Peru
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT   (ABSTRACT 98)
Michael A Horberg
Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INFLAMMATION, EXERCISE CAPACITY, CHRONOTROPY, AND SYMPTOMS IN POST-ACUTE COVID-19   (ABSTRACT 99)
Matthew S. Durstenfeld
University of California, San Francisco, San Francisco, CA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
SALIVA, NASAL & TEAR PK OF EIDD-1931 IN PATIENTS WITH COVID-19 RECEIVING MOLNUPIRAVIR   (ABSTRACT 100)
Laura Dickinson
University of Liverpool, Liverpool, United Kingdom
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART I
Laura Dickinson
University of Liverpool, Liverpool, United Kingdom
Douglas D Richman
University of California San Diego, La Jolla, CA, USA
Matthew S. Durstenfeld
University of California, San Francisco, San Francisco, CA, USA
Jorge A Gallardo-Cartagena
Universidad Nacional Mayor de San Marcos, Bellavista, CALLAO, Peru
Michael A Horberg
Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, MD, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-COV-2 INFECTION IN INDIA   (ABSTRACT 101)
Nagalingeswaran Kumarasamy
Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
INTRAMUSCULAR SOTROVIMAB IS NONINFERIOR TO INTRAVENOUS SOTROVIMAB FOR COVID-19   (ABSTRACT 102)
Anita Kohli
Arizona Clinical Trials, Chandler, AZ, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
EFFECT OF SEROSTATUS ON THE EFFICACY OF SOTROVIMAB IN PREVENTING COVID-19 PROGRESSION   (ABSTRACT 103)
Adrienne E Shapiro
University of Washington, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
CASIRIVIMAB AND IMDEVIMAB COMBINATION PROVIDES LONG-TERM PROTECTION AGAINST COVID-19   (ABSTRACT 104)
Meagan P O'Brien
Regeneron Pharmaceuticals Incorporated, Tarrytown, NY, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
CAMOSTAT IS NOT EFFECTIVE FOR MILD-MODERATE COVID-19 IN A PHASE II TRIAL OF ACTIV-2   (ABSTRACT 105)
Nikolaus Jilg
Massachusetts General Hospital, Boston, MA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
LIVE QUESTIONS AND ANSWERS PART II
Leah A Gaffney
Vir Biotechnology, MELROSE, MA, USA
Huldrych F G√ľnthard
University Hospital Zurich, Zurich, Switzerland
Nikolaus Jilg
Massachusetts General Hospital, Boston, MA, USA
Nagalingeswaran Kumarasamy
Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India
Meagan P O'Brien
Regeneron Pharmaceuticals Incorporated, Tarrytown, NY, USA
Adrienne E Shapiro
University of Washington, Seattle, WA, USA
from CROI 2022 on February 15, 2022 9:45 AM-11:45 AM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 11 of 11